Skip to Content
Merck
All Photos(1)

Documents

35485

Supelco

2,4′-DDD

PESTANAL®, analytical standard

Synonym(s):

1-(2-Chlorophenyl)-1-(4-chlorophenyl)-2,2-dichloroethane, (2,4′-Dichlorodiphenyl)dichloroethane, o,p′-DDD, Mitotane

Sign Into View Organizational & Contract Pricing


About This Item

Linear Formula:
(ClC6H4)2CHCHCl2
CAS Number:
Molecular Weight:
320.04
Beilstein:
2056007
EC Number:
UNSPSC Code:
41116107
PubChem Substance ID:
NACRES:
NA.24

grade

analytical standard

Quality Level

product line

PESTANAL®

shelf life

limited shelf life, expiry date on the label

technique(s)

HPLC: suitable
gas chromatography (GC): suitable

application(s)

agriculture
environmental

format

neat

SMILES string

ClC(Cl)C(c1ccc(Cl)cc1)c2ccccc2Cl

InChI

1S/C14H10Cl4/c15-10-7-5-9(6-8-10)13(14(17)18)11-3-1-2-4-12(11)16/h1-8,13-14H

InChI key

JWBOIMRXGHLCPP-UHFFFAOYSA-N

Gene Information

Looking for similar products? Visit Product Comparison Guide

Related Categories

General description

2,4′-DDD is generally used to reduce the endogenous CORT neuropeptide, which might mask the total population of intracellular corticosteroid receptors in sparrows. It is an adrenal specific agent, which can find potent applications in the treatment of adrenocortical carcinoma (ACC).

Application

Refer to the product′s Certificate of Analysis for more information on a suitable instrument technique. Contact Technical Service for further support.

Legal Information

PESTANAL is a registered trademark of Merck KGaA, Darmstadt, Germany

Pictograms

Health hazard

Signal Word

Warning

Hazard Statements

Hazard Classifications

Carc. 2

Storage Class Code

11 - Combustible Solids

WGK

WGK 3

Flash Point(F)

Not applicable

Flash Point(C)

Not applicable

Personal Protective Equipment

dust mask type N95 (US), Eyeshields, Gloves

Choose from one of the most recent versions:

Certificates of Analysis (COA)

Lot/Batch Number

Don't see the Right Version?

If you require a particular version, you can look up a specific certificate by the Lot or Batch number.

Already Own This Product?

Find documentation for the products that you have recently purchased in the Document Library.

Visit the Document Library

Customers Also Viewed

Slide 1 of 1

1 of 1

Optimal treatment of adrenocortical carcinoma with mitotane: results in a consecutive series of 96 patients
Haak.R.H, et al.
British Journal of Cancer, 69(5), 947-951 (1994)
Pharmacological characterization of intracellular, membrane, and plasma binding sites for corticosterone in house sparrows
Breuner.WC and Orchinik M
General and Comparative Endocrinology, 163(1), 214-224 (2009)
Mitotane for adrenocortical carcinoma treatment
SH and MF
Current Opinion in Investigational Drugs, 6(4), 386-394 (2005)
Lawrence S Kirschner
Trends in endocrinology and metabolism: TEM, 23(7), 343-350 (2012-05-26)
Adrenocortical carcinoma (ACC) is a rare cancer for which few treatment options have been available. Currently, the best available treatment involves combination chemotherapy with the adrenolytic drug mitotane, although the response rate remains modest. Over the past 10 years there
A Redlich et al.
Klinische Padiatrie, 224(6), 366-371 (2012-11-13)
Adrenocortical cancer (ACC) in childhood is a rare disease with poor prognosis. Complete surgical resection, systemic chemotherapy, and mitotane therapy are important curative treatment options for patients with advanced-stage tumors. Since 1997, pediatric ACC patients in Germany have been treated

Our team of scientists has experience in all areas of research including Life Science, Material Science, Chemical Synthesis, Chromatography, Analytical and many others.

Contact Technical Service